|
|
 |
|
Viewing report
|
|
|
|
Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact
Drug and Market Development Publishing, Aug 2005, Pages: 188
1 Executive Summary
PDE Enzyme Families
Selective PDE Inhibitors
Technological Developments
Therapeutic Potential
Market Potential
Future Perspectives
2 Introduction
Signal Transduction
Cyclic Nucleotides
Cyclic Nucleotide Phosphodiesterases
Objectives and Scope
3 Review of Phosphodiesterases
History and Milestones
PDE Categorization and Nomenclature
General Molecular Biology
PDEs and Tissue Distribution
PDEs and Physiological Processes
Review of PDE Families (Molecular Biology and Therapeutic Potential)
4 Selective PDE Inhibitors and Current Drug Pipelines
Introduction
PDEs as Attractive Drug Targets
Selective PDE5 Inhibitors
Selective PDE3 Inhibitors
Selective PDE4 Inhibitors
Selective PDE Inhibitors and Other PDE Families
5 Technology and Approaches to PDE Drug Discovery
Introduction
Functional Studies of PDEs as Drug Targets
Structural Studies of PDEs as Drug Targets
PDEs and Diagnostics
6 Current Challenges in PDE Inhibitor Drug Development
Introduction
Desired Inhibitor Characteristics and Associated Challenges
Chronology of PDE Inhibitor Development
Summary of Current Challenges
7 Therapeutic Potential and Selective PDE Inhibitors
Introduction
Erectile Dysfunction
Peripheral Arterial Disease
Asthma
COPD
Learning and Memory Disorders
Depression
Cross-indications
Other Diseases
8 Market Potential and Selective PDE Inhibitors
Introduction
Market Activity Per PDE Inhibitor Family
Market Activity Per Therapeutic Area
Market Landscape
Market Potential
9 Future Perspectives
Introduction
PDEs and Therapeutic and Market Potential
PDE Inhibitor Discovery
PDEs and Clinical Pipelines
PDEs and The Patient
Summary
10 Company Profiles
11 Interviews with Industry Experts
Gideon Bollag, PhD., Plexxikon, Inc (Berkeley, California)
Thomas Kronbach PhD., elbion AG (Radebeul, Germany)
Cesare Mondadori, PhD., Neuro3d S.A (Mulhouse, France)
John Dietrich, PhD., VIVUS, Inc (Mountain View, California)
Dr. Swaroop Kumar Vakkalanka., Glenmark Pharmaceuticals Ltd (Mumbai, India)
Customers who bought this item also bought
Phoenix PDE
Competitor Analysis: HDAC Inhibitors
Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications
Competitor Analysis: Elastase Inhibitors
Histone Deacetylase inhibitors
Competitor Analysis: Raf Inhibitors
Competitor Analysis: Protein Kinase C (PKC) Inhibitors
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
Competitor Analysis: Bcr-Abl and Src Kinase Inhibitors
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
|
|
|
|
